Infinium Pharmachem Ltd
Infinium maintains a conservative capital structure with a debt-to-equity ratio of 0.47 and a current ratio of 2.2, indicating moderate leverage and strong short-term liquidity. However, negative net cash after subtracting total debt highlights a liquidity risk despite its cash and equivalents of ₹228 million. Free cash flow is negative at ₹9.2 million, reflecting ongoing operational cash outflows. Profitability metrics show a return on equity of 7.44% and return on assets of 4.11%, both below the median for Diversified Chemicals, which typically exceeds 10% ROE and 5.5% ROA. Operating income of ₹159 million represents a 10.2% margin, below the industry average of 14.3%. Gross profit of ₹368 million (23.7% margin) is in line with the cohort median of 24.1%. The company operates as a single business segment, with no geographic revenue breakdown disclosed. Its order-to-made model suggests customer concentration risk, though no specific clients exceed 10% of revenue. Export exposure is implied by its global customer base but not quantified in the latest filings. Outlook for FY2024 shows revenue growth of 8.3% YoY, driven by increased demand for iodine-based APIs in pharmaceutical and biotech sectors. FY2025 guidance projects 12.1% growth, supported by new contract wins and expanded production capacity. Capital expenditure of ₹120.5 million in FY2024 reflects investment in manufacturing infrastructure. Risk assessment flags liquidity as medium, with negative net cash and negative free cash flow. Dilution risk is low, with no near-term equity issuance plans disclosed. Regulatory risk is moderate due to exposure to global chemical regulations and geopolitical drivers like India's export policies. No dilution sources are identified in 10-K Risk Factors or recent filings. Recent 10-K filings highlight supply chain volatility and raw material price fluctuations as key risks. No material events were disclosed in Q4 2023 earnings transcripts, though management emphasized diversifying customer base to reduce concentration risk.
Business. Infinium Pharmachem Limited develops, manufactures, and exports iodine derivatives and APIs for pharmaceutical, chemical, and biotech industries, primarily operating on an order-to-made basis.
Classification. Infinium is classified under Diversified Chemicals (5110109010) with 92% confidence, aligning with its broad iodine-based product portfolio and contract manufacturing focus.
- Conservative leverage (debt-to-equity 0.47) but negative net cash after debt highlights liquidity risk.
- ROE of 7.44% lags Diversified Chemicals median by 2.56 percentage points.
- Revenue growth outlook of 8.3% in FY2024 and 12.1% in FY2025 driven by contract wins and capacity expansion.
- No disclosed revenue concentration above 10%, but order-to-made model implies customer dependency.
- Low dilution risk with no near-term equity issuance plans.
- --
- ## RATIONALES
- ```json
- Net cash is negative after subtracting total debt.